高级检索
当前位置: 首页 > 详情页

Low preoperative prognostic nutritional index predicts poor survival in patients with newly diagnosed high-grade gliomas

文献详情

资源类型:
机构: [1]Sun Yat Sen Univ, Dept Neurosurg Neurooncol, Canc Ctr, State Key Lab Oncol South China,Collaborat Innova, Guangzhou, Guangdong, Peoples R China; [2]Cent S Univ, Key Lab Translat Radiat Oncol, Dept Radiat Oncol, Hunan Canc Hosp,Affiliated Canc Hosp,Xiangya Sch, Changsha, Hunan, Peoples R China
出处:
ISSN:

关键词: Prognosis High-grade gliomas Prognostic nutritional index Survival

摘要:
Preoperative prognostic nutritional index (PNI) has been widely demonstrated to predict survival of patients with malignant tumors. Its utility in predicting outcomes in patients with high-grade gliomas (HGG) remains undefined. A retrospective study of 188 HGG patients was conducted. An optimal PNI cut-off value was applied to stratify patients into high PNI (ae<yen>52.55, n = 78) and low PNI (< 52.55, n = 110) groups. Univariate and multivariate analysis was performed to identify prognostic factors associated with overall survival (OS) and progression free survival (PFS). The resulting prognostic models were externally validated using a demographic-matched cohort of 130 HGG patients. In the training set, PNI value was negatively correlated with age (p = 0.027) and tumor grade (p = 0.048). Both PFS (8.27 vs. 20.77 months, p < 0.001) and OS (13.57 vs. 33.23 months, p < 0.001) were significantly worse in the low PNI group. Strikingly, patients in high PNI group had a 52% decrease in the risk of tumor progression and 55% decrease of death relative to low PNI. Multivariate analysis further demonstrated PNI as an independent predictor for PFS (HR = 0.62, 95% CI 0.43-0.87) and OS (HR = 0.56, 95% CI 0.38-0.80). The PNI retained independent prognostic value in the validation set for both PFS (p = 0.013) and OS (p = 0.003). On subgroup analysis by tumor grade and treatment modalities, both PFS and OS were better for the patients with high PNI. The PNI is a potentially valuable preoperative marker for the survival of patients following HGG resection.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 3 区 医学
小类 | 3 区 临床神经病学 3 区 肿瘤学
最新[2023]版:
大类 | 2 区 医学
小类 | 3 区 临床神经病学 3 区 肿瘤学
第一作者:
第一作者机构: [1]Sun Yat Sen Univ, Dept Neurosurg Neurooncol, Canc Ctr, State Key Lab Oncol South China,Collaborat Innova, Guangzhou, Guangdong, Peoples R China;
通讯作者:
通讯机构: [1]Sun Yat Sen Univ, Dept Neurosurg Neurooncol, Canc Ctr, State Key Lab Oncol South China,Collaborat Innova, Guangzhou, Guangdong, Peoples R China;
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43374 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号